Peter Robins, from Metabolic Health Solutions (MHS), describes how a new clinical management tool can help individualise treatment of obesity and Type 2 diabetes
The number of people diagnosed with diabetes in the UK has doubled in the last 20 years and is responsible for 26,000 early deaths per year alongside serious complications such as blindness, amputation or stroke.
According to NHS Digital, the cost of prescription medication in 2018 exceeded £1 billion, an increase of more than £420 million since 2008. However, the cost of medication represents only a small fraction of the total burden (>£14 billion), such is the devastating and expensive complications associated with the disease(1,2).
Approximately 90% have Type 2 diabetes (T2D), a progressive condition characterised by diminished rates of fatty acid oxidation in the fasting state and the inability to efficiently switch to glucose oxidation in the post-prandial state(3). This phenomenon, which invariably associates with excess weight, has been termed metabolic inflexibility(4,5) and results in insulin resistance together with a steadily progressive beta cell defect.
“I have used an ECAL machine in my General Practice for 1 year in a total of 35 patients with significant obesity, pre-diabetes, and diabetes. It is now an invaluable tool, I would now not wish to be without…
“Patients are significantly more motivated than when discussing weight, bloods or waist alone. Through dietary change and regular tests patients immediately see and track the effect on their ability to burn fat which is directly related to insulin and insulin resistance…
I can see huge potential for this in the health service.”
Source – Open Access